Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 223 clinical trials
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective:

<ul>
  • To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B
    • ul>

    Secondary Objective:

    <ul>
  • To characterize the safety and tolerability
  • To characterize the pharmacokinetics (PK)
    • ul>

    fitusiran
    antihemophilic factor
    factor ix
    haemophilia a
    bethesda assay
    • 0 views
    • 19 Feb, 2024
    • 6 locations
    Multi-center Open-label Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

    Primary Objectives:

    <ul>
  • To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV)
  • To evaluate the pharmacokinetics (PK) of SC and IV isatuximab
    • ul>

    Secondary Objectives:

    <ul>
  • To estimate absolute bioavailability of SC and IV isatuximab
  • To measure receptor occupancy (RO) after isatuximab SC versus IV …

    hepatitis b surface antigen
    corticosteroids
    premedication
    refractory multiple myeloma
    pomalidomide
    • 0 views
    • 19 Feb, 2024
    • 13 locations
    Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

    ul>

    • 0 views
    • 19 Feb, 2024
    • 23 locations
    Study of Lademirsen (SAR339375) in Patients With Alport Syndrome  

    ul>

    • 0 views
    • 29 Nov, 2024
    • 20 locations
    Venglustat in Combination With Cerezyme in Adult and Pediatric Patients With Gaucher Disease Type 3

    ul>

    • 0 views
    • 19 Feb, 2024
    • 7 locations
    Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

    Primary Objectives:

    <ul>
  • Safety run-in: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM)
  • Randomized Phase 3: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival when …

    dexamethasone
    bone marrow procedure
    lenalidomide
    multiple myeloma
    isatuximab
    • 0 views
    • 19 Feb, 2024
    • 16 locations
    Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

    Primary Objectives:

    <ul>
  • Safety run-in: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM)
  • Randomized Phase 3: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival when compared …

    dexamethasone
    bone marrow procedure
    lenalidomide
    multiple myeloma
    isatuximab
    • 0 views
    • 19 Feb, 2024
    • 11 locations
    Systematic Evaluation of Ablation Techniques for Non-Paroxysmal Atrial Fibrillation.

    The purpose of this study is to evaluate the safety and effectiveness of empirical posterior wall isolation (PWI), left atrial appendage electrical isolation (LAAEI) and coronary sinus isolation (CSI) when compared to pulmonary vein isolation (PVI) alone:

    <ul>
  • PVI alone,
  • PVI + PWI,
  • PVI + PWI + LAAEI,
  • PVI …

    pulmonary vein isolation
    chest pain
    paroxysmal atrial fibrillation
    ablation techniques
    left ventricular dysfunction
    • 0 views
    • 19 Feb, 2024
    Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B With or Without Inhibitory Antibodies to Factor VIII or IX

    Primary Objective:

    To characterize the long-term safety and tolerability of fitusiran

    Secondary Objectives:

    <ul>
  • To characterize the long-term efficacy of fitusiran as assessed by the frequency of:
  • Bleeding episodes
  • Spontaneous bleeding episodes
  • Target joint bleeding episodes
  • To characterize the effects of fitusiran on health-related quality of life (HRQOL) …

    fitusiran
    antihemophilic factor
    haemophilia a
    hemarthrosis
    hemophilia
    • 0 views
    • 19 Feb, 2024
    • 41 locations
    SAR408701 Versus Docetaxel in Previously Treated Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients

  • The primary objective is to determine whether SAR408701 improves the overall survival (OS) when compared with docetaxel in participants with metastatic non-squamous NSCLC expressing CEACAM5 2+ in intensity in at least 50% of the tumor cell population and previously treated with standard-of-care platinum-based chemotherapy and an immune checkpoint inhibitor.
    • ul>

    …

    lung cancer
    docetaxel
    small cell lung cancer
    non-squamous non-small cell lung cancer
    platinum-based chemotherapy
    • 0 views
    • 19 Feb, 2024
    • 169 locations